Andrew Limper, MD, on the Effectiveness of Antifibrotics for IPF

In this podcast, Andrew Limper, MD, discusses his latest research on 2 antifibrotic drugs for the treatment of idiopathic pulmonary fibrosis, which was recently published by the American Thoracic Society.

Andrew H. Limper, MD, is the Robert D. and Patricia E. Kern Associate Dean of Practice Transformation and Walter and Leonore Annenberg Professor of Pulmonary Medicine at Mayo Clinic in Rochester, Minnesota. He is also a pulmonary and critical care physician at Mayo Clinic in Rochester, Minnesota, and a professor of Biochemistry and Molecular Biology and Medicine at the Mayo Clinic College of Medicine and Science.

Additional Reading:

• Dempsey TM, Sangaralingham LR, Yao X, Sanghavi D, Shah ND, Limper AH. Clinical effectiveness of antifibrotic medications for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2019;200(2):168-174. https://doi.org/10.1164/rccm.201902-0456OC. 

Published in partnership with